Hereditary gout in a young woman with allopurinol intolerance


DOI: https://dx.doi.org/10.18565/therapy.2023.6.106-113

Garanin A.A., Lebedev P.A., Paranina E.V.

Samara State Medical University of the Ministry of Healthcare of Russia
Abstract. The article examines a clinical case of hereditary gout in a young woman with intolerance to allopurinol and the development of joint deformities, which caused a severe course with disability. A feature of this case is the atypical clinical picture of polyarthritis in the onset with the involvement of large and small joints in a young woman. The dynamics of the development of the patient’s pathological condition is presented, demonstrating the complexity of the treatment of this disease. The administration of febuxostat made it possible to reduce the level of hyperuricemia; however, by this time the patient was disabled due to the formation of multiple deformities of large and small joints of the upper and lower extremities.
Keywords: febuxostat, gout, hyperuricemia, allopurinol
Read entire article

Literature

1. Шостак Н.А., Правдюк Н.Г., Демидова Н.А. Подагра – клинические проявления у лиц пожилого возраста, современные аспекты терапии (клиническое наблюдение). Поликлиника. 2018; (1–1): 50–55. [Shostak N.A., Pravdyuk N.G., Demidova N.A. Gout-clinical manifestations in the elderly, modern aspects of therapy (clinical observation). Poliklinika = Polyclinics. 2018; (1–1): 50–55 (In Russ.)]. EDN: URMUEG.


2. Закирова В.Б., Галяутдинов Г.С., Скрябина Е.В. с соавт. Клинический случай наблюдения пациента с подагрой и метаболическим синдромом. Вестник современной клинической медицины. 2010; 3(3): 60–62. [Zakirova V.B., Galyautdinov G.S., Skryabina E.V. et al. Clinical case of a patient with gout and metabolic syndrome. Vestnik sovremennoy klinicheskoy meditsiny = Bulletin of Contemporary Clinical Medicine. 2010; 3(3): 60–62 (In Russ.)]. EDN: NDZWXD.


3. Елисеев М.С., Чикаленкова Н.А., Денисов И.С., Барскова В.Г. Факторы риска подагры: половые различия. Научно-практическая ревматология. 2011; 49(6): 28–31. [Eliseev M.S., Chikalenkova N.A., Denisov I.S, Barskova B.G. Risk factors for gout: Gender differences. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011; 49(6): 28–31 (In Russ.)]. EDN: PBJYJV.


4. Елисеев М.С., Чикаленкова Н.А., Барскова В.Г. Клинические особенности подагры у женщин: результаты сравнительного исследования. Научно-практическая ревматология. 2014; 52(2): 178–182. [Eliseev M.S., Chikalenkova N.A., Barskova V.G. Clinical features of gout in women: results of a comparative study. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014; 52(2): 178–182 (In Russ.)] https://dx.doi.org/10.14412/1995-4484-2014-178-182. EDN: SMYQVN.


5. Селицкая О.В., Клеменков С.В. Особенности течения подагры у женщин. Сибирский медицинский журнал (Иркутск). 2007; 74(7): 113–114. [Selitskaya O.V., Klemenkov S.V. Features of the course of gout in women. Sibirskiy meditsinskiy zhurnal (Irkutsk) = Siberian Medical Journal (Irkutsk). 2007; 74(7): 113–114 (In Russ.)]. EDN: PBCQOV.


6. Каледа М.И., Никишина И.П., Зокиров Н.З. с соавт. Опыт применения комбинации фебуксостата и канакинумаба при тофусной подагре, осложнившейся хронической болезнью почек, у пациента подросткового возраста: клиническое наблюдение. Вопросы современной педиатрии. 2018; 17(5): 399–407. [Kaleda M.I., Nikishina I.P., Zokirov N.Z. et al. Experience of using a combination of febuxostat and kanakinumab for tofus gout, complicated by chronic kidney disease, in a patient of adolescent age: clinical observation. Voprosy sovremennoy pediatrii = Current Pediatrics. 2018; 17(5): 399–407 (In Russ.)].https://dx.doi.org/10.15690/vsp.v17i5.1957. EDN: YOTVWP.


7. Wallace K.L., Riedel A.A., Joseph-Ridge N., Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004; 31(8): 1582–87.


8. Насонов Е.Л., Насонова В.А., Барскова В.Г. Механизмы развития подагрического воспаления. Терапевтический архив. 2006; 78(6): 77–84. [Nasonov E.L., Nasonova V.A., Barskova V.G. Mechanisms of development of gouty inflammation. Terapevticheskiy arkhiv = Therapeutic Archive. 2006; 78(6): 77–84 (In Russ.)]. EDN: HTTLIZ.


9. Richette P., Doherty M., Pascual E. et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020; 79(1): 31–38. https://dx.doi.org/10.1136/annrheumdis-2019-215315.


10. Клинические рекомендации. Подагра. Ассоциация ревматологов России. 2018. Доступ: https://ivgma.ru/attachments/46946 (дата обращения – 01.08.2023). [Clinical guidelines. Gout. Association of Rheumatologists of Russia. 2018.URL: https://ivgma.ru/attachments/46946 (date of access – 01.08.2023) (In Russ.)].


11. Robinson P.C. Gout – An update of aetiology, genetics, co-morbidities and management. Maturitas. 2018; 118: 67–73.https://dx.doi.org/10.1016/j.maturitas.2018.10.012.


12. Цурко В.В., Елисеева М.Е., Воробьев П.А. Особенности течения подагры в пожилом возрасте. Терапевтический архив. 2014; 86(5): 50–55. [Tsurko V.V., Eliseeva M.E., Vorobyev P.A. Features of the course of gout in the elderly. Terapevticheskiy arkhiv = Therapeutic Archive. 2014; 86(5): 50–55 (In Russ.)]. EDN: SVNJAN.


13. Nakazawa F., Ishihara H., Tanaka K. A case of female premenopausal tophaceous gout requiring surgical management. Mod Rheumatol. 2004; 14(5): 383–87. https://dx.doi.org/10.3109/s10165-004-0327-0.


14. Чепнян Д.А., Сажнова С.И. Клинический случай развития подагры на фоне терапии диуретиками. Бюллетень медицинских интернет-конференций. 2013; 3(3): 756. [Chepnyan D.A., Sazhnova S.I. A clinical case of gout development on the background of diuretic therapy. Byulleten’ meditsinskikh internet-konferentsiy = Bulletin of Medical Internet Conferences. 2013; 3(3): 756 (In Russ.)]. EDN: PVWJGV.


15. Keiichiro K., Maiko K., Hiroko N. et al. Tophaceous gout in anorexia nervosa. General Med. 2013; 14(1): 61–63.https://dx.doi.org/10.14442/general.14.61.


16. Grobner W., Walter-Sack I., de Vires J.X. Disease specific noncompliance with drug treatment as a cause of persistent hyperuricemia and gout in anorexia nervosa. Eur J Med Res. 1998; 3(1–2): 77–80.


17. Chen C.J., Tseng C.C., Yen J.H. et al. ABCG2 contributes to the development of gout and hyperuricemia in a genome-wide association study. Sci Rep. 2018; 8(1): 3137. https://dx.doi.org/10.1038/s41598-018-21425-7.


18. Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практическая ревматология. 2004; 42(1): 5–7. [Nasonova V.A., Barskova V.G. Early diagnosis and treatment of gout is a scientifically based requirement for improving the labor and life prognosis of patients. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2004; 42(1): 5–7 (In Russ.)]. EDN: QCWYZP.


19. FitzGerald J.D., Dalbeth N., Mikuls T. et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020; 72(6): 879–95. https://dx.doi.org/10.1002/art.41247.


20. Schumacher H.R., Becker M.A., Wortmann R.L. et al. The FOCUS trial 48-month interim analysis: Long-term clinical. outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open label extension study [abstract no. OP0130]. Ann Rheum Dis. 2006; 65(2): 93.


21. Елисеев М.С., Шаяхметова Р.У. Опыт применения фебуксостата у пациента с тяжелой инвалидизирующей подагрой. Современная ревматология. 2017; 11(3): 81–84. [Eliseev M.S., Shayakhmetova R.U. Experience with febuxostat in a patient with severe disabling gout. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017; 11(3): 81–84 (In Russ.)].https://dx.doi.org/10.14412/1996-7012-2017-3-81-84. EDN: ZHNWVL.


22. Bardin T., Chales G., Pascart T. et al. Risk of cutaneous adverse events with febuxostate treatment in patients with skin reaction to allopurinol. Joint Bone Spine. 2016; 83(3): 314–17. https://dx.doi.org/10.1016/j.jbspin.2015.11.


23. Lin C.W., Huang W.I., Chao P.H. Risk of cutaneous adverse reactions associate with allopurinol or febuxostat in real world patients: a real world study. Int J Clin Pract. 2019; 73(5): e13316. https://dx.doi.org/10.1111/ijcp.13316.


24. Елисеев М.С. Комментарии к обновленным рекомендациям американской коллегии ревматологов по лечению подагры. Уратснижающие препараты (часть 1). Современная ревматология. 2020; 14(3): 117–24. Eliseev M.S. Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2020; 14(3): 117–24 (In Russ.)].https://dx.doi.org/10.14412/1996-7012-2020-3-117-124. EDN: ZWBFIO.


25. Sundy J.S., Becker M.A., Baraf H.S. et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum. 2008; 58(9): 2882–91. https://dx.doi.org/10.1002/art.23810.


About the Autors

Andrey A. Garanin, PhD in Medical Sciences, director of the Scientific and Practical Center for Distance Medicine, Samara State Medical University of the Ministry of Healthcare of Russia. Address: 443079, Samara, 165B Karla Marksa Avenue. E-mail: a.a.garanin@samsmu.ru. ORCID: https://orcid.org/0000-0001-6665-1533
Petr A. Lebedev, MD, professor, head of the Department of therapy of the Institute of professional education with a course of functional diagnostics, Samara State Medical University of the Ministry of Healthcare of Russia. Address: 443095, Samara, 159 Tashkentskaya Str. ORCID: https://orcid.org/0000-0003-3501-2354
Elena V. Paranina PhD in Medical Sciences, associate professor, associate professor of the Department of therapy of the Institute of professional education with a course of functional diagnostics, Samara State Medical University of the Ministry of Healthcare of Russia. Address: 443095, Samara, 159 Tashkentskaya Str.
E-mail: eles77@list.ru. ORCID: https://orcid.org/0000-0001-7021-4061


Similar Articles

Back to Content

Бионика Медиа